FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200510289> ?p ?o ?g. }

• W4200510289 endingPage "799" @default.
• W4200510289 startingPage "788" @default.
• W4200510289 abstract "•More advanced disease severity in non-alcoholic fatty liver disease is associated with a specific composition of fecal fungi. •Changes are particularly present in non-obese patients. •Systemic antibodies against Candida albicans are increased in patients with non-alcoholic fatty liver disease and advanced fibrosis. •Antifungals protect germ-free fecal microbiome-humanized mice from Western diet-induced steatohepatitis. Background & Aims Studies investigating the gut-liver axis have largely focused on bacteria, whereas little is known about commensal fungi. We characterized fecal fungi in patients with non-alcoholic fatty liver disease (NAFLD) and investigated their role in a fecal microbiome-humanized mouse model of Western diet-induced steatohepatitis. Methods We performed fungal internal transcribed spacer 2 sequencing using fecal samples from 78 patients with NAFLD, 16 controls and 73 patients with alcohol use disorder. Anti-Candida albicans (C. albicans) IgG was measured in blood samples from 17 controls and 79 patients with NAFLD. Songbird, a novel multinominal regression tool, was used to investigate mycobiome changes. Germ-free mice were colonized with feces from patients with non-alcoholic steatohepatitis (NASH), fed a Western diet for 20 weeks and treated with the antifungal amphotericin B. Results The presence of non-obese NASH or F2-F4 fibrosis was associated with a distinct fecal mycobiome signature. Changes were characterized by an increased log-ratio for Mucor sp./Saccharomyces cerevisiae (S. cerevisiae) in patients with NASH and F2-F4 fibrosis. The C. albicans/S. cerevisiae log-ratio was significantly higher in non-obese patients with NASH when compared with non-obese patients with NAFL or controls. We observed a different fecal mycobiome composition in patients with NAFLD and advanced fibrosis compared to those with alcohol use disorder and advanced fibrosis. Plasma anti-C. albicans IgG was increased in patients with NAFLD and advanced fibrosis. Gnotobiotic mice, colonized with human NASH feces and treated with amphotericin B were protected from Western diet-induced steatohepatitis. Conclusions Non-obese patients with NAFLD and more advanced disease have a different fecal mycobiome composition to those with mild disease. Antifungal treatment ameliorates diet-induced steatohepatitis in mice. Intestinal fungi could be an attractive target to attenuate NASH. Lay summary Non-alcoholic fatty liver disease is one of the most common chronic liver diseases and is associated with changes in the fecal bacterial microbiome. We show that patients with non-alcoholic fatty liver disease and more severe disease stages have a specific composition of fecal fungi and an increased systemic immune response to Candida albicans. In a fecal microbiome-humanized mouse model of Western diet-induced steatohepatitis, we show that treatment with antifungals reduces liver damage. Studies investigating the gut-liver axis have largely focused on bacteria, whereas little is known about commensal fungi. We characterized fecal fungi in patients with non-alcoholic fatty liver disease (NAFLD) and investigated their role in a fecal microbiome-humanized mouse model of Western diet-induced steatohepatitis. We performed fungal internal transcribed spacer 2 sequencing using fecal samples from 78 patients with NAFLD, 16 controls and 73 patients with alcohol use disorder. Anti-Candida albicans (C. albicans) IgG was measured in blood samples from 17 controls and 79 patients with NAFLD. Songbird, a novel multinominal regression tool, was used to investigate mycobiome changes. Germ-free mice were colonized with feces from patients with non-alcoholic steatohepatitis (NASH), fed a Western diet for 20 weeks and treated with the antifungal amphotericin B. The presence of non-obese NASH or F2-F4 fibrosis was associated with a distinct fecal mycobiome signature. Changes were characterized by an increased log-ratio for Mucor sp./Saccharomyces cerevisiae (S. cerevisiae) in patients with NASH and F2-F4 fibrosis. The C. albicans/S. cerevisiae log-ratio was significantly higher in non-obese patients with NASH when compared with non-obese patients with NAFL or controls. We observed a different fecal mycobiome composition in patients with NAFLD and advanced fibrosis compared to those with alcohol use disorder and advanced fibrosis. Plasma anti-C. albicans IgG was increased in patients with NAFLD and advanced fibrosis. Gnotobiotic mice, colonized with human NASH feces and treated with amphotericin B were protected from Western diet-induced steatohepatitis. Non-obese patients with NAFLD and more advanced disease have a different fecal mycobiome composition to those with mild disease. Antifungal treatment ameliorates diet-induced steatohepatitis in mice. Intestinal fungi could be an attractive target to attenuate NASH." @default.
• W4200510289 created "2021-12-31" @default.
• W4200510289 creator A5001918029 @default.
• W4200510289 creator A5002417517 @default.
• W4200510289 creator A5006812064 @default.
• W4200510289 creator A5007202760 @default.
• W4200510289 creator A5009763145 @default.
• W4200510289 creator A5012576740 @default.
• W4200510289 creator A5025288190 @default.
• W4200510289 creator A5028249844 @default.
• W4200510289 creator A5033558108 @default.
• W4200510289 creator A5037877480 @default.
• W4200510289 creator A5039106310 @default.
• W4200510289 creator A5041189105 @default.
• W4200510289 creator A5055219188 @default.
• W4200510289 creator A5057927715 @default.
• W4200510289 creator A5062529299 @default.
• W4200510289 creator A5063150466 @default.
• W4200510289 creator A5064828949 @default.
• W4200510289 creator A5070710980 @default.
• W4200510289 creator A5083825910 @default.
• W4200510289 creator A5091812870 @default.
• W4200510289 date "2022-04-01" @default.
• W4200510289 modified "2023-10-17" @default.
• W4200510289 title "The fecal mycobiome in non-alcoholic fatty liver disease" @default.
• W4200510289 cites W2051705700 @default.
• W4200510289 cites W2056396392 @default.
• W4200510289 cites W2060736880 @default.
• W4200510289 cites W2061894085 @default.
• W4200510289 cites W2080591639 @default.
• W4200510289 cites W2093217993 @default.
• W4200510289 cites W2139894595 @default.
• W4200510289 cites W2153997209 @default.
• W4200510289 cites W2616380171 @default.
• W4200510289 cites W2744057697 @default.
• W4200510289 cites W2761761695 @default.
• W4200510289 cites W2770129291 @default.
• W4200510289 cites W2909142264 @default.
• W4200510289 cites W2937834684 @default.
• W4200510289 cites W2940966064 @default.
• W4200510289 cites W2951061751 @default.
• W4200510289 cites W2951719120 @default.
• W4200510289 cites W2973208413 @default.
• W4200510289 cites W2997236134 @default.
• W4200510289 cites W3033611565 @default.
• W4200510289 cites W3048394674 @default.
• W4200510289 cites W3089718558 @default.
• W4200510289 doi "https://doi.org/10.1016/j.jhep.2021.11.029" @default.
• W4200510289 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34896404" @default.
• W4200510289 hasPublicationYear "2022" @default.
• W4200510289 type Work @default.
• W4200510289 citedByCount "54" @default.
• W4200510289 countsByYear W42005102892022 @default.
• W4200510289 countsByYear W42005102892023 @default.
• W4200510289 crossrefType "journal-article" @default.
• W4200510289 hasAuthorship W4200510289A5001918029 @default.
• W4200510289 hasAuthorship W4200510289A5002417517 @default.
• W4200510289 hasAuthorship W4200510289A5006812064 @default.
• W4200510289 hasAuthorship W4200510289A5007202760 @default.
• W4200510289 hasAuthorship W4200510289A5009763145 @default.
• W4200510289 hasAuthorship W4200510289A5012576740 @default.
• W4200510289 hasAuthorship W4200510289A5025288190 @default.
• W4200510289 hasAuthorship W4200510289A5028249844 @default.
• W4200510289 hasAuthorship W4200510289A5033558108 @default.
• W4200510289 hasAuthorship W4200510289A5037877480 @default.
• W4200510289 hasAuthorship W4200510289A5039106310 @default.
• W4200510289 hasAuthorship W4200510289A5041189105 @default.
• W4200510289 hasAuthorship W4200510289A5055219188 @default.
• W4200510289 hasAuthorship W4200510289A5057927715 @default.
• W4200510289 hasAuthorship W4200510289A5062529299 @default.
• W4200510289 hasAuthorship W4200510289A5063150466 @default.
• W4200510289 hasAuthorship W4200510289A5064828949 @default.
• W4200510289 hasAuthorship W4200510289A5070710980 @default.
• W4200510289 hasAuthorship W4200510289A5083825910 @default.
• W4200510289 hasAuthorship W4200510289A5091812870 @default.
• W4200510289 hasBestOaLocation W42005102892 @default.
• W4200510289 hasConcept C126322002 @default.
• W4200510289 hasConcept C145081991 @default.
• W4200510289 hasConcept C2778772119 @default.
• W4200510289 hasConcept C2779134260 @default.
• W4200510289 hasConcept C2779478299 @default.
• W4200510289 hasConcept C2780917455 @default.
• W4200510289 hasConcept C61716771 @default.
• W4200510289 hasConcept C71924100 @default.
• W4200510289 hasConcept C86803240 @default.
• W4200510289 hasConcept C89423630 @default.
• W4200510289 hasConcept C90924648 @default.
• W4200510289 hasConceptScore W4200510289C126322002 @default.
• W4200510289 hasConceptScore W4200510289C145081991 @default.
• W4200510289 hasConceptScore W4200510289C2778772119 @default.
• W4200510289 hasConceptScore W4200510289C2779134260 @default.
• W4200510289 hasConceptScore W4200510289C2779478299 @default.
• W4200510289 hasConceptScore W4200510289C2780917455 @default.
• W4200510289 hasConceptScore W4200510289C61716771 @default.
• W4200510289 hasConceptScore W4200510289C71924100 @default.
• W4200510289 hasConceptScore W4200510289C86803240 @default.
• W4200510289 hasConceptScore W4200510289C89423630 @default.
• W4200510289 hasConceptScore W4200510289C90924648 @default.

• next